vs
Side-by-side financial comparison of Q32 Bio Inc. (QTTB) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.
Roivant Sciences Ltd. is the larger business by last-quarter revenue ($2.0M vs $1.9M, roughly 1.0× Q32 Bio Inc.). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -13301.2%, a 16292.4% gap on every dollar of revenue.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
QTTB vs ROIV — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9M | $2.0M |
| Net Profit | $57.7M | $-265.9M |
| Gross Margin | — | — |
| Operating Margin | — | -16966.1% |
| Net Margin | 2991.2% | -13301.2% |
| Revenue YoY | — | -77.8% |
| Net Profit YoY | 506.9% | -257.0% |
| EPS (diluted) | $4.70 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9M | $2.0M | ||
| Q3 25 | $-220.0K | $1.6M | ||
| Q2 25 | $-284.0K | $2.2M | ||
| Q1 25 | $-371.0K | $-39.6M | ||
| Q4 24 | $0 | $9.0M | ||
| Q3 24 | $0 | $4.5M | ||
| Q2 24 | $0 | $8.0M | ||
| Q1 24 | $0 | $28.9M |
| Q4 25 | $57.7M | $-265.9M | ||
| Q3 25 | $-7.4M | $-113.5M | ||
| Q2 25 | $-9.5M | $-223.4M | ||
| Q1 25 | $-11.0M | $-206.5M | ||
| Q4 24 | $-14.2M | $169.4M | ||
| Q3 24 | $-17.6M | $-230.2M | ||
| Q2 24 | $-17.0M | $95.3M | ||
| Q1 24 | $1.0M | $-151.1M |
| Q4 25 | — | -16966.1% | ||
| Q3 25 | 3444.1% | -19492.9% | ||
| Q2 25 | 3229.2% | -13130.0% | ||
| Q1 25 | 3296.0% | 674.8% | ||
| Q4 24 | — | -3042.6% | ||
| Q3 24 | — | -7636.0% | ||
| Q2 24 | — | -1279.5% | ||
| Q1 24 | — | -919.5% |
| Q4 25 | 2991.2% | -13301.2% | ||
| Q3 25 | 3358.6% | -7225.9% | ||
| Q2 25 | 3341.2% | -10292.9% | ||
| Q1 25 | 2973.3% | 521.8% | ||
| Q4 24 | — | 1878.3% | ||
| Q3 24 | — | -5143.8% | ||
| Q2 24 | — | 1192.7% | ||
| Q1 24 | — | -522.3% |
| Q4 25 | $4.70 | $-0.38 | ||
| Q3 25 | $-0.60 | $-0.17 | ||
| Q2 25 | $-0.78 | $-0.33 | ||
| Q1 25 | $-0.90 | $-0.28 | ||
| Q4 24 | $2.63 | $0.23 | ||
| Q3 24 | $-1.46 | $-0.31 | ||
| Q2 24 | $-1.42 | $0.12 | ||
| Q1 24 | $-6.33 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $48.3M | $4.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $42.0M | $4.3B |
| Total Assets | $61.8M | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.3M | $4.5B | ||
| Q3 25 | $49.0M | $4.4B | ||
| Q2 25 | $54.8M | $4.5B | ||
| Q1 25 | $65.5M | $4.9B | ||
| Q4 24 | $78.0M | $5.1B | ||
| Q3 24 | $89.1M | $5.4B | ||
| Q2 24 | $97.7M | $5.7B | ||
| Q1 24 | $115.5M | $6.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $311.7M | ||
| Q1 24 | — | $430.6M |
| Q4 25 | $42.0M | $4.3B | ||
| Q3 25 | $-18.4M | $4.4B | ||
| Q2 25 | $-12.2M | $4.3B | ||
| Q1 25 | $-4.0M | $4.7B | ||
| Q4 24 | $5.7M | $5.2B | ||
| Q3 24 | $18.3M | $5.2B | ||
| Q2 24 | $33.5M | $5.4B | ||
| Q1 24 | $48.8M | $6.0B |
| Q4 25 | $61.8M | $5.2B | ||
| Q3 25 | $57.8M | $5.1B | ||
| Q2 25 | $66.1M | $5.0B | ||
| Q1 25 | $79.1M | $5.4B | ||
| Q4 24 | $92.3M | $5.8B | ||
| Q3 24 | $104.5M | $6.2B | ||
| Q2 24 | $124.2M | $6.5B | ||
| Q1 24 | $152.3M | $7.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $-196.5M |
| Free Cash FlowOCF − Capex | — | $-201.4M |
| FCF MarginFCF / Revenue | — | -10076.0% |
| Capex IntensityCapex / Revenue | — | 246.9% |
| Cash ConversionOCF / Net Profit | -0.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-776.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $-196.5M | ||
| Q3 25 | $-4.2M | $-185.7M | ||
| Q2 25 | $-10.7M | $-204.4M | ||
| Q1 25 | $-12.5M | $-172.6M | ||
| Q4 24 | $-11.4M | $-207.3M | ||
| Q3 24 | $-19.5M | $-266.8M | ||
| Q2 24 | $-22.2M | $-192.8M | ||
| Q1 24 | $-14.6M | $-108.5M |
| Q4 25 | — | $-201.4M | ||
| Q3 25 | — | $-193.5M | ||
| Q2 25 | — | $-208.4M | ||
| Q1 25 | — | $-173.4M | ||
| Q4 24 | $-11.4M | $-209.1M | ||
| Q3 24 | $-19.6M | $-267.8M | ||
| Q2 24 | $-22.2M | $-193.8M | ||
| Q1 24 | — | $-108.8M |
| Q4 25 | — | -10076.0% | ||
| Q3 25 | — | -12317.8% | ||
| Q2 25 | — | -9604.5% | ||
| Q1 25 | — | 438.1% | ||
| Q4 24 | — | -2318.5% | ||
| Q3 24 | — | -5984.4% | ||
| Q2 24 | — | -2425.5% | ||
| Q1 24 | — | -376.1% |
| Q4 25 | — | 246.9% | ||
| Q3 25 | 0.0% | 499.6% | ||
| Q2 25 | — | 185.9% | ||
| Q1 25 | — | -2.0% | ||
| Q4 24 | — | 20.3% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 1.2% |
| Q4 25 | -0.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.02× | ||
| Q1 24 | -14.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
